SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00331864
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
531
Enrollment
INDUSTRY
Sponsor class
Conditions
Age Related Macular Degeneration
Choroidal Neovascularization
Interventions
DRUG:
Ranibizumab
Sponsor
Novartis